FDG-PET predicts response to chemo in Hodgkin's disease

Article

FDG-PET performed after two cycles of standard chemotherapy can accurately predict which patients with Hodgkin's lymphoma will respond or relapse, according to a multicenter international study.

FDG-PET performed after two cycles of standard chemotherapy can accurately predict which patients with Hodgkin's lymphoma will respond or relapse, according to a multicenter international study.

Dr. Andrea Gallamini and colleagues in Italy and Denmark enrolled 260 advanced Hodgkin's lymphoma patients scheduled to receive six cycles of chemotherapy. Patients underwent F-18 FDG-PET imaging before the first and after the second chemo cycle. Those with positive and negative FDG-PET results at the second chemo cycle recorded a two-year progression-free survival rate of 12.8% and 95%, respectively (J Clin Oncol 2007;25[24]:3746-3752).

The study shows that FDG-PET can be a useful prognostic tool that will help sort patients into appropriate management paths, researchers said.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.